An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).

NCT03583372 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

506

Enrollment

INDUSTRY

Sponsor class

Conditions

Overactive Bladder

Interventions

DRUG: Vibegron
DRUG: placebos
DRUG: Tolterodine Tartrate ER

Sponsor

Urovant Sciences GmbH